Patent Document ID: 8765392
Application ID: 13739250
Patent Flag: 1

Claim One:
1. A method of quantifying the severity of myelodysplastic syndrome (MDS) in a subject, comprising: obtaining a blood sample from a subject with early or late stage MDS; measuring and analyzing a set of predictive parameters in leukocytes from the blood sample of the subject using flow cytometry, wherein said set of predictive parameters comprises polymorphic neutrophil (PMN) granularity and leucocyte expression of CD66, CD11a, CD10, and CD116; assigning a numerical value to each predictive parameter; assigning a numerical score reflecting the predictive parameter values obtained for said leucocytes in said blood sample; comparing the predictive parameters to corresponding predictive parameters of a control sample, wherein said control sample is selected from a (a) subject or pool of subjects without MDS; (b) a subject or pool of subjects with early stage MDS; or (c) a subject or pool of subjects with late stage MDS; and assigning a numerical score reflecting predictive parameter values obtained for the control sample, wherein a score of 3 or greater in the blood sample of the subject indicates the severity of said myelodysplastic syndrome.